Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease

Introduction The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra‐atrial reentrant tachycardia (IART) is well‐described in adults without congenital heart disease (CHD). Data are sparse regarding their use for the same purpose in adults...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cardiovascular electrophysiology 2023-12, Vol.34 (12), p.2545-2551
Hauptverfasser:	Przybylski, Robert, Eberly, Logan M., Alexander, Mark E., Bezzerides, Vassilios J., DeWitt, Elizabeth S., Dionne, Audrey, Mah, Douglas Y., Triedman, John K., Walsh, Edward P., O'Leary, Edward T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult adult congenital heart disease Anti-Arrhythmia Agents - adverse effects Antiarrhythmics Arrhythmia atrial fibrillation Atrial Fibrillation - chemically induced Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Atrial Flutter - diagnosis Atrial Flutter - drug therapy Cardiac arrhythmia Cardiovascular disease Cardioversion Congenital diseases Electric Countershock - adverse effects Fibrillation flecainide Flecainide - adverse effects Heart Defects, Congenital - complications Heart Defects, Congenital - diagnosis Heart Defects, Congenital - therapy Heart diseases Humans intra‐atrial reentrant tachycardia propafenone Propafenone - adverse effects Retrospective Studies Success Tachycardia Tachycardia, Supraventricular - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!